expression levels of lncRNAs are regulated in the cardiac tissue after myocardial infarction (MI), it is unknown whether MI affects the levels of lncRNAs in peripheral blood cells.
Five lncRNAs suspected to be associated with cardiac pathology were investigated in the present study: hypoxia inducible factor 1A antisense RNA 2 (aHIF), cyclin-dependent kinase inhibitor 2B antisense RNA 1 (ANRIL), potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1 (KCNQ1OT1), MIassociated transcript (MIAT), and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1).
We show that expression levels of selected lncRNAs were changed in peripheral blood cells from patients with acute MI and were associated with LV dysfunction.
Methods Patients
Four hundred fourteen patients with acute MI enrolled in the Luxembourg Acute MI Registry and treated with primary percutaneous coronary intervention were enrolled in this study. A total of 274 patients had acute ST-segment-elevation MI (STEMI), which was defined by the following: (1) clinically significant ST-segment elevation (>1 mm); (2) occluded major coronary artery: thrombolysis in MI, 0 flow in the left anterior descending, circumflex, or right coronary artery; (3) peak creatine kinase activity >600 U/L (3× higher than the upper limit of the reference interval). A total of 140 patients had non-ST-segment-elevation MI (NSTEMI), which was defined by the following: (1) no significant ST-segment elevation but clinically significant ST depression (>1 mm); (2) clinically significant lesion in a major coronary artery requiring primary percutaneous coronary intervention; (3) positive troponin T (TnT) concentration after 24 hours (>0.03 µg/L). Majority of patients with NSTEMI presented with a severe or subocclusive lesion in the left anterior descending, circumflex, or right coronary artery. Blood samples were obtained at the time of mechanical reperfusion, via an arterial catheter and into PAXgene RNA tubes (BD Biosciences, Erembodegem, Belgium). LV ejection fraction was determined at 4-month follow-up by echocardiography. The protocol has been approved by the local ethics committee, and all patients signed an informed consent. In addition, arterial blood samples were obtained from 86 apparently healthy volunteers (ie, without apparent signs of cardiovascular disease).
Isolation of Different Leukocyte Subtypes
Enriched fractions of different subtypes of leukocytes were obtained from blood samples of healthy donors. Neutrophils were isolated by Ficoll gradient (MP Biomedicals, Illkirch, France) followed by dextran sedimentation (Amersham, Roosendaal, The Netherlands) as described. 18 Peripheral blood mononuclear cells were isolated by Ficoll gradient in LeucoSep tubes (Greiner Bio One, Wemmel, Belgium), and monocytes were purified from peripheral blood mononuclear cells by negative selection using the Monocyte Isolation Kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as described. 19 Nonmonocyte cells, that is, T cells, B cells, natural killer cells, dendritic cells, and basophils retained on the column by the antibody cocktail, were recovered and considered as being predominantly lymphocytes.
Measurement of lncRNAs Expression
This section has been described in the Online Data Supplement. Expression values of lncRNAs of each patient with MI have been adjusted by whole blood cell count.
Biochemical Analyses
Cardiac troponin T was measured using a fourth-generation assay from Roche performed on a Cobas e601 equipment, 0.01 µg/L being the lower detection limit and 0.03 µg/L being the cardiac troponin T concentration reproducibly measured with a coefficient of variation <10%. Creatine phosphokinase (CPK) activity was measured with a Roche IFCC recommended method on a Cobas c501 instrument. N-terminal pro-brain natriuretic peptide was measured using an Elecsys E2010 analyzer with N-terminal pro-brain natriuretic peptide reagent pack (Roche Diagnostics). The detection limit of this assay is 1 pg/mL.
Statistical Analyses
Mann-Whitney test was used to compare 2 groups of continuous variables. χ 2 test was used for qualitative data. One-way ANOVA followed by all pairwise multiple comparison procedures using the Holm-Sidak method was used for multiple groups comparisons. Linear regression and Spearman rank correlations were used to evaluate the association between levels of lncRNAs and continuous variables, and logistic regression was used for dichotomized variables. The SigmaPlot version 12.0 software was used for statistical analyses. All tests were 2 tailed, and a P<0.05 was considered significant.
To evaluate the prognostic value of lncRNAs, receiver operating characteristic (ROC) curves were constructed, and the area under the ROC curves was determined. Univariable analyses with logistic regression was used to evaluate the ability of lncRNAs to predict LV dysfunction. Multivariable analyses were conducted with logistic regression to determine the predictive value of lncRNAs in conjunction with clinical parameters. Odds ratios with 95% confidence intervals were computed. Analysis of deviance with the Wald χ 2 test to measure significance was performed to address the value of adding a variable to a model. Reclassification analyses were performed to determine the additive value of lncRNAs to clinical parameters and other biomarkers. The integrated discrimination improvement was computed. Prediction analyses were performed on the R version 2.14.2 statistical platform using the packages hmisc, survival, and splines. 
Results

Characteristics of the Study Population
Levels of lncRNAs in Healthy Volunteers and Patients With MI
First of all, considering that each patient with MI enrolled in this study received a bolus of heparin and that heparin can affect DNA amplification by polymerase chain reaction, we verified that heparin did not affect the measurement of lncRNAs by polymerase chain reaction (Online Figure I) .
Then, we compared the levels of lncRNAs in whole blood cells obtained in PAXgene tubes from patients with MI and healthy volunteers ( Figure 1A ). MALAT1 was expressed at a high level; MIAT was moderately expressed; aHIF, ANRIL, and KCNQ1OT1 were expressed at lower levels. Levels of aHIF, KCNQ1OT1, and MALAT1 were higher in patients with MI when compared with healthy volunteers. Levels of ANRIL were lower in patients with MI when compared with healthy volunteers, and levels of MIAT were similar in both groups.
Association Between Levels of lncRNAs and Inflammation Markers in Patients With MI
There were positive associations between aHIF and several markers of inflammation measured at admission, such as white blood cell count, percentage of neutrophils, and c-reactive protein. In contrast, aHIF was inversely associated with the percentage of lymphocytes ( Table 2) . ANRIL was positively associated with the percentage of lymphocytes and monocytes but was inversely associated with white blood cell count, neutrophils, and platelets. MIAT was positively associated with lymphocytes and negatively associated with neutrophils and ACE indicates angiotensin-converting enzyme; CK, creatine kinase; cTnT, cardiac troponin T; CRP, c-reactive protein; EF, ejection fraction; MI, myocardial infarction; MMP, matrix metalloproteinase; NSTEMI, non-ST-segment-elevation MI; NT-proBNP, N-terminal pro-brain natriuretic peptide; and TIMP, tissue inhibitor of metalloproteinase-1.
platelets. MALAT1 was negatively associated with platelets. KCNQ1OT1 did not show any significant association with inflammatory markers.
Of note, aHIF was also associated with matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1, and ANRIL was associated with matrix metalloproteinase 9 ( Table 2 ).
Association Between Cardiovascular Risk Factors and Levels of lncRNAs
We determined whether the levels of lncRNAs in blood cells of patients with MI were influenced by cardiovascular risk factors ( Table 2 ). Levels of ANRIL were significantly associated with age and diabetes mellitus. The elderly had higher levels of ANRIL, and patients with diabetes mellitus had in average 1.3-fold higher levels of ANRIL (P<0.001). All 5 ln-cRNAs except KCNQ1OT1 were associated with hypertension. MALAT1 was associated with diabetes mellitus and MIAT with smoking.
Levels of lncRNAs According to Diagnosis of STEMI Versus NSTEMI
Considering the association between lncRNAs and inflammation markers, the levels of lncRNAs were adjusted with the white blood cell count of each patient with MI in subsequent analyses.
Patients with STEMI had lower levels of ANRIL, KCNQ1OT1, MIAT, and MALAT1 when compared with patients with NSTEMI ( Figure 1B ). Levels of aHIF were comparable between patients with NSTEMI and STEMI.
Levels of lncRNAs According to the Number of Diseased Coronary Arteries
One hundred seventy-one patients with MI had 1-vessel disease; 144 patients had 2-vessel disease; and 94 patients had 3-vessel disease. Information was not documented for 5 patients. Levels of lncRNAs were comparable between patients with 1, 2, or 3 diseased coronary arteries ( Figure 2 ).
Levels of lncRNAs in Subtypes of Leukocytes
Next, we investigated the expression of lncRNAs in different subtypes of leukocytes isolated from the blood of healthy donors ( Figure 3 ). aHIF was predominantly expressed by monocytes, and MIAT was predominantly expressed by lymphocytes. ANRIL and MALAT1 showed a similar expression profile with a predominance in monocytes and lymphocytes. KCNQ1OT1 was preferentially expressed by neutrophils and monocytes. Of note, in these samples from healthy donors, we could confirm the high level of MALAT1 observed in samples from patients with MI ( Figure 1 ). These data suggest that lncRNAs have distinct expression patterns in the different populations of blood leukocytes. None of the 5 lncRNAs investigated could be consistently detected into serum, plateletenriched, or platelet-deprived plasma of healthy volunteers (Ct value >32; Online Figure II ).
Association Between Levels of lncRNAs and Ischemic Time
To gain insights into the kinetic of the changes in expression of lncRNAs after MI, we determined the ischemic time of each patient with MI (ie, the delay between chest pain onset and revascularization). Ischemic time was available for 402 patients and was in ≈5 hours. There was no linear relationship between ischemic time and levels of lncRNAs ( Figure 4A ). Then, patients were categorized in 3 groups according to ischemic time: <3 hours (=early presenters; n=173), 3 to 6 hours (n=141), and >6 hours (n=88). Patients presenting within 3 hours of chest pain onset had elevated levels of aHIF when compared with patients presenting later on ( Figure 4B ). Together with the observation that levels of aHIF are higher in patients with MI when compared with healthy volunteers ( Figure 1A) , these data suggest that levels of aHIF are dynamically regulated after MI, with a rapid elevation in the first 3 hours after MI, and a decline over the next few hours.
Prediction of LV Dysfunction by lncRNAs
Analysis of ROC curves, univariable and multivariable analyses with logistic regression models, analysis of deviance, and reclassification analyses were implemented to determine the value of lncRNAs to predict LV dysfunction after MI, as demonstrated by an ejection fraction ≤40% at 4-month follow-up. Among the 414 patients enrolled in this study, 6 patients died within the first 4 months. A total of 332 patients (80%) had an echocardiography at 4-month follow-up, and 62 patients (19%) had an ejection fraction ≤40%. The following clinical variables were included in multivariable models and reclassification analyses: age, body mass index, sex, ischemic time, CPK, cardiac troponin T, N-terminal pro-brain natriuretic peptide, white blood cells count, antecedent of MI, diabetes mellitus, hypertension, hypercholesterolemia, and smoking.
ROC curves analysis revealed that lncRNAs were weak predictors of LV dysfunction at 4 months ( Figure 5A ). Using logistic regression, ANRIL, KCNQ1OT1, MIAT, and MALAT1 were significant univariate predictors of LV dysfunction ( Figure 5B ). However, this prediction capacity was lost in multivariate analysis in which only peak levels of CPK (odds ratios [95% confidence interval], 0.9997 [0.9994-1.0000]) and diabetes mellitus (odds ratio [95% confidence interval], 0.33 [0.14-0.82]) remained significant predictors of LV dysfunction ( Figure 5C ). Analysis of deviance showed that addition of ANRIL, KCNQ1OT1, or MALAT1 to a model including all clinical variables improved the prediction ( Table 3) . Combinations of markers did not improve the prediction. ANRIL and KCNQ1OT1 correctly reclassified a significant proportion of patients misclassified by the multivariable clinical model ( Table 3 ). ANRIL and KCNQ1OT1 combined did not induce a further improvement of prediction. All together, these data suggest that ANRIL and KCNQ1OT1 may help in prediction of LV dysfunction.
Discussion
In this study, we show that expression levels of selected ln-cRNAs in peripheral blood cells are regulated after MI, are correlated with markers of cardiac injury, are affected by cardiovascular risk factors, and are associated with prognosis.
Peripheral blood cells were chosen as template to measure levels of lncRNAs. In addition to be noninvasive and convenient, this approach has already been proven valuable to identify transcriptomic signatures useful for the diagnosis of coronary artery disease in high-risk patients. 20 In addition, RNA expression profiles of blood cells and cardiomyocytes share common features in response to aldosterone treatment in hypertensive rats and are associated with pathological remodeling. 21 The rationale for the selection of the 5 lncRNAs investigated in this study is as follows. aHIF, a natural antisense transcript of HIF1α, is overexpressed in the failing heart. 22 By modulating the stability of HIF1α messenger RNA, aHIF has the capacity to regulate angiogenesis, an important component of the response of the heart to ischemia. ANRIL is the best replicated genetic risk factor for coronary artery disease 23 and regulates genes involved in glucose and fatty acid metabolism. 24 KCNQ1OT1 regulates KCNQ1 expression, which deficiency induces congenital long-QT syndrome that can trigger arrhythmias. 25 KCNQ1OT1 acts at the epigenetic level, promoting the formation of repressive chromatin structure, and is involved in cardiac development. 26 MIAT is a long intergenic noncoding RNA mainly expressed in the nervous system. Genome-wide association studies revealed that genetic variation of MIAT confers susceptibility to MI. 27 However, a causal link between MIAT and MI has not yet been demonstrated. MALAT1, which has been recently renamed nuclear-enriched noncoding transcript 2 because of its accumulation in the nucleus, 28 was selected because it regulates alternative splicing and thereby has a strong potential to regulate gene expression and disease. Also, MALAT1 is one of the most highly abundant lncRNAs in mammalian cells. However, to date, MALAT1 has not been associated with heart disease. First of all, this study shows that expression levels of selected lncRNAs in blood cells of patients are extremely variable, some lncRNAs being expressed at a low level (eg, aHIF and ANRIL) and others being highly expressed such as MALAT1. Second, we observed that levels of most of the lncRNAs investigated in this study are regulated in blood cells of patients with acute MI when compared with healthy volunteers. Activation of inflammation most probably contributed to the regulation of lncRNA levels in patients with MI. However, the finding that not all lncRNAs are upregulated in patients with MI suggests that changes in lncRNA levels are not a mere consequence of inflammation. Indeed, levels of ANRIL were lower in patients with MI when compared with healthy volunteers. To correct for a potential bias induced by activation of inflammation, expression levels of lncRNAs were adjusted to the whole blood cell count of each patient with MI. Of note, whole blood cell counts of healthy volunteers were not available.
Levels of aHIF were strongly upregulated in patients with MI. This observation is consistent with the induction of HIF by hypoxia and suggests an interplay between HIF and aHIF in the regulation of angiogenesis after MI. The functional role of aHIF and other lncRNAs in the infarcted heart requires further investigation. Third, the observation that aHIF is correlated with white blood cell count and c-reactive protein suggests that the increased expression of this lncRNA may be a direct consequence of the inflammatory response to MI. Investigation of the expression of lncRNAs in different populations of blood cells from healthy donors revealed that monocytes and neutrophils are the main source of aHIF. Several indicators suggest that the upregulation of aHIF in patients with MI is mostly because of neutrophils. First, blood samples from patients with MI were obtained in the acute phase after MI (<12 hours after symptom onset), a phase where mostly neutrophils become activated. Second, there is a strong positive association between aHIF and the percentage of circulating neutrophils. Third, levels of aHIF are negatively associated with ischemic time, showing a decrease in the first few hours after symptom onset. However, it seems that ANRIL is mostly expressed by lymphocytes after MI because it is expressed both by lymphocytes and by monocytes in healthy donors and it is positively associated with lymphocyte count in patients with MI. This observation is intriguing and, together with the concept Figure 3 . Levels of long noncoding RNAs (lncRNAs) in leukocyte subsets. Peripheral blood was obtained from healthy donors (n≥4) and different cell populations were isolated as described in Methods section of this article. Levels of lncRNAs were assessed by quantitative polymerase chain reaction using SF3a1 as a reference gene for normalization. Significant P values are indicated. aHIF indicates hypoxia inducible factor 1A antisense RNA 2; ANRIL, cyclin-dependent kinase inhibitor 2B antisense RNA 1; KCNQ1OT1, potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/ antisense transcript 1, MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MIAT, MI-associated transcript; and PBMCs, peripheral blood mononuclear cells. Figure 2 . Levels of long noncoding RNAs (lncRNAs) according to the number of diseased vessels. Levels of lncRNAs were assessed by quantitative polymerase chain reaction using SF3a1 as a reference gene for normalization. Values were adjusted by the white blood cell count of each patient with myocardial infarction. A total of 171 patients had 1-vessel disease; 144 patients had 2-vessel disease, and 94 patients had 3-vessel disease. Information was missing for 5 patients. P values are from ANOVA. aHIF indicates hypoxia inducible factor 1A antisense RNA 2; ANRIL, cyclin-dependent kinase inhibitor 2B antisense RNA 1; KCNQ1OT1, potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1, MALAT1, metastasis-associated lung adenocarcinoma transcript 1; and MIAT, MI-associated transcript. September 12, 2014 that lymphocytes play a critical role after MI, 29, 30 suggests that ANRIL might be involved in the response of the heart to ischemic injury. It would be interesting to determine whether ANRIL modulates cardiac function through its known effects on glucose and fatty acid metabolism. 24 Levels of ANRIL were found to be associated with age, diabetes mellitus, and hypertension. We previously reported significant associations between circulating levels of cardiac-enriched microRNAs and cardiovascular risk factors in patients with MI. 31 As for ANRIL, the strongest association between microRNAs and cardiovascular risk factors was age, suggesting that aging affects blood levels of multiple types of RNAs.
Levels of aHIF were positively correlated with CPK and troponin T. This is consistent with an association between aHIF and infarct severity, albeit there was no association with the number of diseased arteries. On the opposite, levels of MIAT were lower in patients with STEMI and were negatively correlated with CPK and troponin T. This suggests that expression of lncRNAs in blood cells is not a mere representation of infarct severity and thereby may provide additional information instead of traditional biomarkers of cardiac injury. The following clinical variables were included in multivariable analyses: age, body mass index, sex, ischemic time (ie, delay between chest pain onset and reperfusion), peak levels of creatine phosphokinase (CPK), and cardiac troponin T (cTnT), admission level of N-terminal pro-brain natriuretic peptide (NT-proBNP), white blood cells count (WBC), antecedent of MI, diabetes mellitus, hypertension (HT), hypercholesterolemia, and smoking. The areas under the ROC curves and odds ratios (OR) with 95% confidence intervals (CIs) were computed. aHIF indicates hypoxia inducible factor 1A antisense RNA 2; ANRIL, cyclin-dependent kinase inhibitor 2B antisense RNA 1; KCNQ1OT1, potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1, MALAT1, metastasis-associated lung adenocarcinoma transcript 1; and MIAT, MI-associated transcript.
An added value of lncRNAs was indeed found when we investigated the ability of lncRNAs to predict LV dysfunction at 4-month follow-up as demonstrated by an ejection fraction ≤40%. Although lncRNAs were weak predictors of LV dysfunction in ROC curve analysis, multivariable analyses attested that KCNQ1OT1 and ANRIL enhanced the predictive value of a multiparameter model, including demographic features, clinical data, and cardiac biomarkers. Determination of the deviance of logistic regression models and reclassification analyses supported an additive value of lncRNAs in prediction of LV dysfunction. Of note, in multivariable analyses, only CPK and diabetes mellitus were significant predictors of LV dysfunction. N-terminal pro-brain natriuretic peptide had a borderline predictive value (P=0.06). The additive predictive value of ANRIL and KCNQ1OT1 is consistent with the absence of correlation with CPK and with the markers of extracellular matrix turnover matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1, which have been shown to be potential indicators of LV remodeling after MI. [32] [33] [34] [35] [36] [37] Additional studies are warranted to address the prognostic value of lncRNAs after MI specifically.
Recent studies reported that cardiac and plasma levels of ln-cRNAs are regulated after MI and can be useful predictors of LV remodeling. 17, 38 The 5 lncRNAs investigated in our study were not reliably detected into serum, platelet-enriched, or plateletdeprived plasma of healthy volunteers. This observation does not exclude their expression in serum or plasma of patients with MI. 11, 12 In addition, in mice subjected to pressure overload, Lee et al 39 identified 135 responsive lncRNAs. Yang et al 13 characterized the transcriptomic profiles of failing human hearts using deep sequencing and reported the regulation of many different lncRNAs. These studies constitute a reservoir for future investigations of the role of lncRNAs in MI and cardiac failure.
Boeckel et al 40 reported that heparin affects the quantification of microRNAs by polymerase chain reaction in human blood samples. Because all patients with MI enrolled in the study received a bolus of 5000 IU of heparin, we tested a potential confounding effect of heparin on levels of lncRNAs. We observed that heparin did not affect the quantification of lncRNAs. This apparent discrepancy with the study by Boeckel et al 40 can have several explanations. First, the concentration of heparin in patient blood (1 IU/mL of blood) is lower than in heparinized blood collection tubes (11-32 IU/mL). Second, RNA preparation from PAXgene tubes does not require a phenol-chloroform extraction step, which has been performed to measure microR-NAs in the study by Boeckel et al, 40 and which copurifies nucleic acids with heparin. 41 Third, we have measured lncRNAs, whereas Boeckel et al 40 have measured microRNAs, which may be more sensitive to interference by heparin than lncRNAs.
This study is limited by the subjective selection of the ln-cRNAs. We expect that many other lncRNAs are regulated after MI and possess a prognostic value. Large-scale technologies, such as next-generation sequencing, would provide an unbiased approach. A second limitation relies on the lack of white blood cells count for the control group that prevented adjusting the levels of lncRNAs to the inflammatory status for the comparison between patients with MI and healthy volunteers. A third limitation relies on the identification of the subtypes of blood cells expressing lncRNAs has been performed on enriched population of cells obtained from healthy volunteers. Definite identification of the cell population expressing lncRNAs after MI would require concomitant assessment of lncRNAs and specific blood cell markers in blood samples from patients with MI. Finally, this study is limited by the absence of independent validation. Thus, the results should be considered provisional requiring validation through replication in independent study populations and experimentation.
In conclusion, we have shown that several lncRNAs are dysregulated in peripheral blood cells of patients with acute The additive value of lncRNAs to a multivariable clinical model to predict LV dysfunction at 4-month (ejection fraction, ≤40%) was evaluated using analysis of deviance and reclassification analyses. The following clinical variables were included in the multivariable model: age, body mass index, sex, ischemic time, creatine phosphokinase, cardiac troponin T, N-terminal pro-brain natriuretic peptide, white blood cells count, antecedent of myocardial infarction, diabetes mellitus, hypertension, hypercholesterolemia, and smoking. The change in deviance indicates the difference between the deviance of the clinical model and the deviance of the clinical model including lncRNAs. Because better performing models have smaller deviance, a decrease in deviance indicates an improvement of prediction. aHIF indicates hypoxia inducible factor 1A antisense RNA 2; ANRIL, cyclin-dependent kinase inhibitor 2B antisense RNA 1; CI, confidence interval; IDI, integrated discrimination improvement; KCNQ1OT1, potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense transcript 1; lncRNAs, long noncoding RNAs; LV, left ventricle; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; and MIAT, myocardial infarction-associated transcript. *Significant P values. September 12, 2014 MI and may be useful for prognostication of outcome. These findings encourage future studies to determine the value of lncRNAs as novel cardiac biomarkers and therapeutic targets. 
Sources of Funding
